SCHEMBL4180952

SCHEMBL4180952

O=C1Nc2c(cccc2-c2ccsc2)C1=O

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CES1 P23141 4/20 0.50
DAO P14920 2/20 0.50
NSD2 O96028 1/20 0.50
BCHE P06276 1/20 0.50
L3MBTL1 Q9Y468 1/20 0.49
LIG1 P18858 1/20 0.46
PTPRC P08575 1/20 0.44
CASP3 P42574 1/20 0.40
CASP2 P42575 1/20 0.40
CASP7 P55210 1/20 0.40
CASP6 P55212 1/20 0.40
CASP8 Q14790 1/20 0.40
MAOB P27338 2/20 0.39
MAOA P21397 1/20 0.39
TMIGD3 P0DMS9 1/20 0.38
ADORA2A P29274 1/20 0.38
ADORA1 P30542 1/20 0.38
CYP2E1 P05181 1/20 0.37
CYP2A6 P11509 1/20 0.37
CYP2B6 P20813 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3847092 0.78 CES1 (0.47) CES1L3MBTL1PTPRCCASP3CASP2
SCHEMBL950588 0.77 CES1 (0.58) CES1DAONSD2BCHEL3MBTL1
SCHEMBL8980802 0.75 CHEK1 (0.44) PTPRCCASP3CASP2CASP7CASP6
SCHEMBL17038519 0.72 L3MBTL1 (0.55) CES1DAONSD2BCHEL3MBTL1
SCHEMBL4189712 0.70 CES1 (0.50) CES1DAONSD2BCHEL3MBTL1
SCHEMBL26259994 0.69 CYP2A6 (0.52) PTPRCMAOBTMIGD3ADORA2AADORA1
SCHEMBL27554975 0.69 PTPRC (0.54) NSD2L3MBTL1PTPRCMAOBMAOA
SCHEMBL30775278 0.69 CLK4 (0.56) GSK3BSLK
SCHEMBL17038548 0.69 L3MBTL1 (0.55) CES1DAONSD2BCHEL3MBTL1
SCHEMBL4946960 0.69 CYP2A6 (0.64) PTPRCMAOBTMIGD3ADORA2AADORA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2134692-A2 QUINOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM FOR SELECTIN INHIBITION Wyeth a Corporation of the State of Delaware (US) 2009-12-23 EP disclosed
US-20090076077-A1 Methods and Compositions for Selectin Inhibition WYETH (US) 2009-03-19 US disclosed
US-20090076077-A1 Methods and Compositions for Selectin Inhibition WYETH (US) 2009-03-19 US disclosed
US-20090076077-A1 Methods and Compositions for Selectin Inhibition WYETH (US) 2009-03-19 US disclosed
US-7465799-B2 Methods and compositions for selectin inhibition WYETH (US) 2008-12-16 US disclosed
US-7465799-B2 Methods and compositions for selectin inhibition WYETH (US) 2008-12-16 US disclosed
US-7465799-B2 Methods and compositions for selectin inhibition WYETH (US) 2008-12-16 US disclosed
US-20080255192-A1 2-(1-(4-chlorophenyl)cyclopropyl)-3-hydroxy-8-(trifluoromethoxy)quinoline-4-carboxylic acid; antiinflammtory agents; antagonists of the mammalian adhesion proteins WYETH (US) 2008-10-16 US disclosed
WO-2008121817-A2 QUINOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM FOR SELECTIN INHIBITION WYETH (US) 2008-10-09 WO disclosed
CN-1902179-A Methods and compositions for selectin inhibition WYETH CORP (US) 2007-01-24 CN disclosed
EP-1682511-A2 METHODS AND COMPOSITIONS FOR SELECTIN INHIBITION Wyeth (US) 2006-07-26 EP disclosed
WO-2005047257-A2 METHODS AND COMPOSITIONS FOR SELECTIN INHIBITION WYETH (US) 2005-05-26 WO disclosed
US-20050101568-A1 Methods and compositions for selectin inhibition WYETH (US) 2005-05-12 US disclosed
US-20030176454-A1 N-coating heterocyclic compounds FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2003-09-18 US disclosed
WO-2001087845-A2 N-CONTAINING HETEROCYCLIC COMPOUNDS AND THEIR USE AS 5-HT ANTAGONISTS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2001-11-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050101568-A1 Methods and compositions for selectin inhibition SELP, SELE, SELL CES1 707/4885DAO 1610/4885NSD2 4259/4885
US-20030176454-A1 N-coating heterocyclic compounds H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, GNE, NIT2 CES1 1914/4885DAO 470/4885NSD2 5/4885
US-20080255192-A1 2-(1-(4-chlorophenyl)cyclopropyl)-3-hydroxy-8-(trifluoromethoxy)quinoline-4-carboxylic acid; antiinflammtory agents; antagonists of the mammalian adhesion proteins VCAM1, ICAM1, SELE CES1 1128/4885DAO 1268/4885NSD2 4420/4885
US-20090076077-A1 Methods and Compositions for Selectin Inhibition SELP, SELE, SELL CES1 883/4885DAO 1574/4885NSD2 4314/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.